Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Pamiparib

SKU: orb1302131

Description

Pamiparib (BGB-290) is a potent, brain-penetrant, and selective PARP1/2 inhibitor with strong PARP-trapping activity. It is widely used in preclinical cancer research, demonstrating efficacy in both in vitro assays and in vivo models for solid tumors, including those with central nervous system involvement.

Research Area

Epigenetics & Chromatin, Molecular Biology

Images & Validation

Key Properties

CAS Number1446261-44-4
MW298.31
Purity99.53% (May vary between batches)
FormulaC16H15FN4O
SMILESC[C@]12CCCN1Cc1n[nH]c(=O)c3cc(F)cc4[nH]c2c1c34
TargetPARP
SolubilityDMSO:62.5 mg/mL (209.51 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (6.7 mM)

Bioactivity

Target IC50
PARP1:0.9 nM|PARP2:0.5 nM
In Vivo
Pamiparib, an investigational Poly (ADP-ribose) polymerase (PARP) inhibitor in clinical development, demonstrates excellent selectivity for both PARP1 and PARP2, and superb anti-proliferation activities in tumor cell lines with BRCA1/2 mutations or HR pathway deficiency (HRD). Pamiparib has good bioavailability and is 16-fold more potent than olaparib in an efficacy study using BRCA1 mutated MDA-MB-436 breast cancer xenograft model. Pamiparib also shows strong anti-tumor synergy with temozolomide (TMZ), a DNA alkylating agent used to treat brain tumors. Compared to other PARP inhibitors, pamiparib demonstrated improved penetration across the blood brain barrier (BBB) in mice. Oral administration of pamiparib at a dose as low as 3 mg/kg is sufficient to abrogate PARylation in brain tumor tissues. In SCLC-derived, TMZ-resistant H209 intracranial xenograft model, combination of pamiparib with TMZ overcomes its resistance and shows significant tumor inhibitory effects and prolonged life span.

Storage & Handling

Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

BGB290, BGB-290, BGB 290, Inhibitor, inhibit, Pamiparib, PARP, PARP1, PARP2, poly ADP ribose polymerase

Similar Products

  • Pamiparib maleate [orb1699723]

    2086689-94-1

    944.859

    C44H42F2N8O14

    50 mg, 100 mg, 25 mg
  • Pamiparib hydrate [orb1739365]

    1858211-28-5

    352.36

    C16H21FN4O4

    50 mg, 100 mg, 25 mg
  • Pamiparib [orb1226263]

    >98% (HPLC)

    1446261-44-4

    298.32

    C16H15FN4O

    2 mg, 5 mg, 100 mg, 200 mg, 500 mg, 1 g
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Protocol Information

Available Sizes

Select a size below

1 mg
$ 70.00
2 mg
$ 80.00
5 mg
$ 90.00
1 ml x 10 mM (in DMSO)
$ 100.00
10 mg
$ 110.00
DispatchUsually dispatched within 5-10 working days
Bulk Enquiry